Astrazeneca releases more COVID-19 vaccine data: 5 things to know

AstraZenecas vaccine trial had actually been halted in the U.S. since Sept. 9, after a participant developed transverse myelitis. The FDA said Oct. 23 that it might resume the trial..

AstraZeneca released an interim analysis of its experimental COVID-19 vaccine Oct. 26 that revealed favorable lead to older populations, The Wall Street Journal reported..

Maia Anderson –
Monday, October 26th, 2020
Print|Email.

5 things to understand about the interim analysis:.

The data showed a lower reactogenicity to the vaccine among older adults, meaning there was a low level of negative effects, such as fever, injection website swelling and body aches. Responses were lower in grownups 56 and older than in younger adults, and reactions minimized after participants received the second dose.

The vaccine showed positive outcomes for grownups 56 and over, particularly those at the higher-risk ages of 70 and older.

More posts on drug store: AstraZeneca, Johnson & & Johnson COVID-19 vaccine trials to resumeEquitas Health, Prism Health North Texas open 2 brand-new pharmacies4 takeaways from the FDA vaccine advisory panel conference.

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this material? View our policies by clicking here.

AstraZeneca CEO Pascal Soriot stated the vaccine would likely supply protection versus contracting COVID-19 for about a year, CNBC reported..

AstraZeneca said its experimental COVID-19 vaccine has actually produced a similar immune reaction in older and younger grownups.

AstraZeneca has actually submitted the interim analysis to a peer-reviewed journal.

© Copyright ASC COMMUNICATIONS 2020. Intrigued in LINKING to or REPRINTING this material? View our policies by clicking here.